ARTICLE | Clinical News
SYN-004: Phase Ib data
February 16, 2015 8:00 AM UTC
Top-line data from a double-blind, placebo-controlled Phase Ib trial in 24 healthy volunteers showed that ascending doses of oral SYN-004 given up to 4 times daily for 7 days led to no safety or toler...